Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
4Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Inhibrx Biosciences, Inc. (INBX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
1Distinct source URLs
7High confidence
0.789Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Inhibrx Biosciences, Inc. Suppliers
Ticker
Name
Confidence
Evidence
OXFORD-FINANCE-LLC
OXFORD-FINANCE-LLC
92%
On January 13, 2025, the Company entered into a Loan and Security Agreement, or the 2025 Loan Agreement, with Oxford Finance LLC, or Oxford, pursuant to which it received $ 100.0 million in gross proceeds.
THIRD-PARTY-CDMOS
THIRD-PARTY-CDMOS
90%
The Company’s usage of third-party CDMOs for clinical and development efforts.
THIRD-PARTY-CROS
THIRD-PARTY-CROS
90%
The Company’s usage of third-party CROs for management of clinical trials.
THIRD-PARTIES
THIRD-PARTIES
85%
The Company’s usage of third-parties for other research and development efforts.
Reciprocal relationship from BCAX graph: Reciprocal relationship from INBX graph: Reciprocal relationship from BCAX graph: Reciprocal relationship from INBX graph: Reciprocal relationship from BCAX g…
Inhibrx Biosciences, Inc. Customers
Ticker
Name
Confidence
Evidence
ANNUAL-REPORT-EMERGING-GROWTH-COMPANY
ANNUAL-REPORT-EMERGING-GROWTH-COMPANY
62%
aths were reported in either arm. The progression-free survival data from the Phase 2 portion of the HexAgon study are expected to become available in the fourth quarter of 2026. We plan to begin the…
Reciprocal relationship from CME graph: Reciprocal relationship from INBX graph: ges with contract development and manufacturing organizations, or CDMOs, for clinical supplies and manufacturing scale…
CME-GROUP
CME-GROUP
62%
ges with contract development and manufacturing organizations, or CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third …
OXFORD-FINANCE-LLC
OXFORD-FINANCE-LLC
62%
aths were reported in either arm. The progression-free survival data from the Phase 2 portion of the HexAgon study are expected to become available in the fourth quarter of 2026. We plan to begin the…
Inhibrx Biosciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
INBX-DEBT
Debt stack $176.3M
90%
Market cache reports total debt of $176.3M.
INBX-DEBT-10273
Warrants outstanding: 0.0001
90%
xbrl warrant detail from xbrl 2025-12-31.
Inhibrx Biosciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Inhibrx Biosciences, Inc..
Inhibrx Biosciences, Inc. Ownership
Holder
Name
Confidence
Evidence
INBX-OWNER-PERCEPTIVE-ADVISORS-LLC
PERCEPTIVE ADVISORS LLC
90%
13F overlay lists PERCEPTIVE ADVISORS LLC as top holder; 140 tracked holders.
Inhibrx Biosciences, Inc. Extended Supply Chain Network
